Akebia Therapeutics, Inc. (AKBA) Financial Analysis and Rating

Comparison Analysis Based on SEC Data

Company Name Akebia Therapeutics, Inc.
Industry (SIC) 2834 - Pharmaceutical Preparations
Revenue in 2025 $236,196 thousand (ranked #172 out of 508 companies in the industry)
Assets as of 12/31/2025 $376,565 thousand (ranked #232)
Market Cap $225,786 thousand (Oct 9, 2026)
Analyzed report 12/31/2024 (filed 3/13/2025)

Year:
20242025

Financial Position and Performance
Annual | Quarterly

Compared with 2024 industry ratios Change during the year

worse
deteriorated
Compared with all listed companies

much worse

Compare with a competitor

Financial Ratios Benchmarking

Financial Ratio Comparison of company ratios for 2024
with industry ratios
(28 - Chemicals And Allied Products) 		with all listed companies
Solvency Ratios
Debt ratio 
1.22
0.48
1.22
0.61
Interest coverage ratio 
-133.26
-4.13
-133.26
2.45
Liquidity Ratios
Current Ratio 
1.41
3.20
1.41
1.78
Quick Ratio 
1.07
1.84
1.07
1.06
Cash Ratio 
0.64
1.81
0.64
0.59
Profitability Ratios
Profit margin 
-43.3%
-108.7%
-43.3%
3%
ROA (Return on assets) 
-29.9%
-25.1%
-29.9%
0.9%
Activity Ratios
Asset turnover (days) 
528
1274
528
776
Receivables turnover (days) 
84
60
84
48
Resulting score -0,8 -1,1

Year:
20242025

Additional Ratios (not used in score calculation)

Financial Ratio Comparison of company ratios for 2024
with industry ratios
(28 - Chemicals And Allied Products) 		with all listed companies
Profitability Ratios
Gross margin 
60.6%
54.8%
60.6%
43.6%
Operating margin (Return on sales) 
-43%
-21.6%
-43%
5.1%
Activity Ratios
Inventory turnover (days) 
93
135
93
88
EBIT  $(69)M
EBITDA  $5M
Price Ratios
Earnings per Share (basic)  $-0.33
Earnings per Share (diluted)  $-0.33

Auditor's Conclusion

We have performed a comparative analysis of the balance sheet and income statement of Akebia Therapeutics, Inc. (hereafter – the "Company") for the year 2024 as filed with the U.S. Securities and Exchange Commission (SEC). The primary business a